Colorectal Cancer Update
A Continuing Medical Education Audio Series
OVERVIEW OF ACTIVITY
Colorectal cancer is among the most common types of cancer in the United States, and the treatment of this disease
continues to evolve. Published results from ongoing clinical trials lead to the emergence of new therapeutic agents and
regimens, changes in the indications, doses and schedules for existing treatments and the development of new genomic
assays and markers with prognostic and/or predictive potential. In order to offer optimal patient care — including the option
of clinical trial participation — the practicing medical oncologist must be well informed of these advances. By providing
access to the latest research developments and expert perspectives, this CME activity assists medical oncologists in the
formulation of up-to-date clinical management strategies.
LEARNING OBJECTIVES
- Utilize assessment of K-ras mutation status to select appropriate patients with colorectal cancer (CRC) who may
benefit from treatment with EGFR inhibitors.
- Develop an evidence-based algorithm for the treatment of metastatic CRC that incorporates the individualized
use of bevacizumab, cetuximab and other biologic agents based on an understanding of their unique efficacy and
tolerability profiles.
- Appraise the clinical value of continuing therapy with biologic agents beyond initial disease progression.
- Recognize patients with isolated CRC hepatic metastases who may be eligible for surgical cure, considering the utility
of conversion therapy and perioperative/postoperative systemic treatments.
- Describe existing and investigational biomarkers used to predict risk of CRC recurrence and/or response to
targeted therapy.
- Identify the clinical and molecular characteristics of hereditary nonpolyposis CRC, and refer patients at high risk
for genetic evaluation.
- Compare and contrast the clinical indications for preoperative and/or postoperative concomitant chemoradiation
therapy among patients with locally advanced rectal cancer.
- Summarize the efficacy and toxicity findings from clinical research combining molecularly targeted agents for the
treatment of advanced CRC.
- Counsel appropriately selected patients with CRC about availability of and participation in ongoing clinical trials.
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing
medical education for physicians.
CREDIT DESIGNATION STATEMENT
Research To Practice designates this educational activity for a maximum of 2.75 AMA PRA Category 1 Credits™.
Physicians should only claim credit commensurate with the extent of their participation in the activity.
HOW TO USE THIS CME ACTIVITY
This CME activity contains an audio component. To receive credit, the participant should review the CME information,
listen to the CDs and complete the Post-test and Educational Assessment and Credit Form located in our website at ResearchToPractice.com/CCU/ThinkTank.
This program is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers
Squibb Company, Genentech BioOncology, Genomic Health Inc and ImClone Systems Incorporated.
